IPO Updates

Amanta Healthcare IPO Date, Review, Price, Allotment Details APPLY OR NOT ?

Published

on

The Amanta Healthcare IPO is creating buzz ahead of its launch in early September 2025. If you are interested in the pharmaceutical sector, this is an offering worth watching. This article explains everything from the IPO date and price band to the allotment process and company background. It will help you decide if the Amanta Healthcare IPO suits your portfolio.


Amanta Healthcare IPO Date and Price Band

The subscription window for the Amanta Healthcare IPO opens on September 1, 2025, and closes on September 3, 2025. Investors will have just three days to apply for shares, so mark your calendar.

IPO Open Date:September 1, 2025
IPO Close Date:September 3, 2025
Face Value:₹10 Per Equity Share
IPO Price Band:₹120 to ₹126 Per Share
Issue Size:Approx ₹126 Crores
Fresh Issue:Approx ₹126 Crores
Lot Size:119 Shares
Issue Type:Book Built Issue
IPO Listing:BSE & NSE
Retail Quota:Not more than 35%
QIB Quota:Not more than 50%
NII Quota:Not more than 15%

Amanta Healthcare plans to issue 10 million fresh equity shares aiming to raise around ₹126 crore. There is no offer for sale (OFS) in this IPO, meaning existing shareholders are not selling any shares. The money from this IPO will go fully to the company for expansion and business needs.


Allotment and Listing Timeline

The IPO allotment will be finalized on September 4, 2025. If you do not get shares, refunds will be processed by September 8. Shares will be credited to investors’ demat accounts by the same date. Trading on NSE and BSE is expected to begin from September 9, 2025.

EVENTDATE
IPO OpenSeptember 1, 2025
IPO CloseSeptember 3, 2025
Share Allotment DateSeptember 4, 2025
Refund and Share CreditSeptember 8, 2025
Listing DateSeptember 9, 2025

About Amanta Healthcare: Company Overview

Amanta Healthcare has been part of India’s pharmaceutical industry since 1994. The company focuses on making sterile liquid formulations. These include large volume parenterals (LVPs) and small volume parenterals (SVPs). These products are important for injectable medicines and intravenous treatments. The company’s manufacturing unit is in Hariyala, Kheda, Gujarat. It follows strict quality systems and holds certifications like:

  • WHO-GMP (World Health Organization – Good Manufacturing Practices)
  • ISO 9001:2015
  • ISO 13485:2016

These certifications show that Amanta Healthcare meets global quality and safety standards. Their plant uses modern machines to ensure consistent product quality and meets tough regulations.

Use of IPO Funds

The funds raised in this IPO will be used mainly for:

  • Adding new production lines for SteriPort (sterile injectable products) and SVP at the current facility
  • General corporate purposes, such as working capital and expansion efforts

This will help Amanta Healthcare increase its production capacity and improve product range to meet rising demand better.


Amanta Healthcare IPO Review and Outlook

The Amanta Healthcare IPO gives investors a chance to enter a focused part of pharma manufacturing. The demand for sterile liquid medicines, especially injectables, is steadily growing in India and around the world.

Strengths of Amanta Healthcare

  • Specialized Products: Focus on parenterals offers a niche market with high-quality standards.
  • Strong Certifications: WHO-GMP and ISO certificates add trust and open doors for export business.
  • Modern Facility: State-of-the-art equipment supports reliable production and scaling.

Risks You Should Know

  • Regulatory Risks: Pharma manufacturing faces tight government controls. Compliance failures or rule changes can hurt the business.
  • Competition: Even in this niche, competition is present. Amanta must innovate and keep quality high to stay relevant.
  • Market Risks: Stock prices of mid-sized pharma firms can fluctuate due to market moods or sector-specific issues.

Still, experts believe the company is positioned well to grow as it uses IPO funds to expand.

Amanta Healthcare IPO Market Lot

The Amanta Healthcare IPO minimum market lot is 119 shares with ₹14,994 application amount. The retail investors can apply up-to 13 lots with 1,547 shares of ₹1,94,922 amount.

ApplicationLot SizeSharesAmount
Retail Minimum1119₹14,994
Retail Maximum131,547₹1,94,922
S-HNI Minimum141,666₹2,09,916
B-HNI Minimum677,973₹10,04,598

Amanta Healthcare Financial Report

The company reported revenue of 276 crores in 2025 against 282 crores in 2024. The company reported profit of 10.50 crores in 2025 against profit of 3.63 crores in 2024.

Amount in Crores

Period EndedRevenueExpensePATAssets
2023₹263₹206₹2.11₹374
2024₹282₹223₹3.63₹352
2025₹276₹215₹10.50₹382

Amanta Healthcare IPO Valuation – FY2025

Check Amanta Healthcare IPO valuations detail like Earning Per Share (EPS), Price/Earning P/E Ratio, Return on Net Worth (RoNW), and Net Asset Value (NAV) details.

KPIValues
ROE:12.42%
ROCE:13.72%
EBITDA Margin:22.11%
PAT Margin:3.86%
Debt to equity ratio:2.02
Earning Per Share (EPS):₹3.71 (Basic)
Price/Earning P/E Ratio:N/A
Return on Net Worth (RoNW):10.89%
Net Asset Value (NAV):₹33.43

How to Apply for Amanta Healthcare IPO

The IPO is open through major stock exchanges NSE and BSE. Investors can apply via:

  • Online trading platforms like Zerodha, HDFC Securities, and Upstox
  • Physical or electronic application forms from registered brokers and financial firms

Remember, you must apply in lots of 119 shares, with one lot as the minimum.

Watch: Amanta Healthcare IPO Review

For those wanting a quick and clear video overview, here is a detailed review explaining the IPO’s key details, price band, and company outlook. This video is a great resource to understand the IPO better before applying. <div align=”center”> Amanta Healthcare IPO Review – YouTube


Social Media and Market Buzz

So far, the Amanta Healthcare IPO has gained visibility across various social platforms. Investors share insights and updates regularly, helping others stay informed.


Final Thoughts

The Amanta Healthcare IPO expected in September 2025 is a promising chance to invest in a pharma company focused on sterile liquids. With a price range of ₹120 to ₹126 and listing set for September 9, it’s worth a look if you want exposure in healthcare. Make sure to study the company’s business, market climate, and risks before investing. Following trusted financial sources and using reliable brokers will help you apply smoothly.


Trending

Exit mobile version